Abstract
Virion immunogens induce a spectrum of antibodies of different specificities. Some of these antibodies can inhibit the cellular expression of the viral genome, i.e., neutralize virus infectivity. Inhibition of virus infectivity is a highly specific reaction, and serologic typing of virus is therefore generally performed by neutralization tests. Neutralizing antibodies play an obvious role in restriction of virus replication, not only in cell cultures but also in vivo. For this reason, potential vaccine products are evaluated for their capacity to induce neutralizing antibodies. Although this approach provides the best guideline at the current stage, it has some inherent caveats. This review provides examples of some of the limitations in the employment of neutralization tests in vaccine studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
